Pfizer will sell Mylan its dry-powder inhaler delivery system in an agreement set to pit the generics firm against UK drug major GlaxoSmithKline (GSK).
BioClinica says increasing interest in CNS disorders will drive the imagining sector; and predicts that pharmas and CROs will want integrated EDC in two years.
